<DOC>
	<DOCNO>NCT00810888</DOCNO>
	<brief_summary>The purpose study determine compute tomography angiography predict individual intracerebral hemorrhage experience significant growth size hemorrhage . For individual high risk hemorrhage growth , study compare drug recombinant activate factor VII ( rFVIIa ) placebo determine effect rFVIIa intracerebral hemorrhage growth .</brief_summary>
	<brief_title>The Spot Sign Predicting Treating ICH Growth Study</brief_title>
	<detailed_description>Intracerebral hemorrhage ( ICH ) —breakage blood vessel bleed brain—is devastate form stroke 40-50 percent fatality rate prove treatment . Because majority death ICH occur within several day stroke , intervention improve outcome must occur early treatment course . Among potentially modifiable determinant ICH outcome , hematoma growth particularly attractive target intervention major focus trial . The purpose study determine image test call compute tomography angiography ( CTA ) predict individual ICH experience significant growth size hemorrhage . Growth hemorrhage cause additional injury may worsen outcome . For individual high risk hemorrhage growth base CTA result ( i.e. , positive CTA `` spot sign , '' evidence contrast leakage within hemorrhage ) , study compare effect drug call recombinant activate factor VII ( NovoSeven® ) rFVIIa placebo determine well reduce ICH growth . The primary goal trial ( 1 ) determine sensitivity specificity CTA spot sign predict hematoma growth ; ( 2 ) determine feasibility use CTA identify individual ICH high risk hematoma growth select study participant randomization treatment rFVIIa placebo ; ( 3 ) determine rate hematoma growth among spot-positive individual 24 hours—comparing individual treat rFVIIa treat placebo . Approximately 184 person ICH enrol one two study group 10 clinical site across United States Canada . Participants ICH determine CTA high risk hemorrhage growth ( CTA `` spot sign '' positive ) randomize receive either active study medication , rFVIIa , 80 mcg/kg , receive placebo ( inactive substance ) . Participants ICH determine CTA high risk hemorrhage growth ( determine CTA `` spot sign '' negative ) enrol prospective observational group . Duration study participant approximately 3 month .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<criteria>Acute , spontaneous ICH ( include bleed cerebellum ) diagnose nonenhanced CT scan within five hour symptom onset . ( Time onset define last time patient witness baseline ( i.e. , subject stroke symptom upon awaken consider onset begin sleep ) Age &gt; /= 18 year 80 year ( candidate must 18th birthday , 81st birthday ) For spot positive patient , dose study drug within 90 minute enrol CT scan Time symptom onset ICH unknown five hour prior baseline CT scan , ICH secondary know suspected trauma , aneurysm , vascular malformation , hemorrhagic conversion ischemic stroke , venous sinus thrombosis , thrombolytic treatment condition ( e.g. , myocardial infarction , cerebral infarction , etc . ) , CNS tumor CNS infection Brainstem location hemorrhage ( patient cerebellar hemorrhage may enrol ) Serum creatinine &gt; 1.4 mg/dl ( 123 μmol/L ) . Sites currently perform CTA standard care ICH follow standard procedure regard renal insufficiency . Known allergy iodinate contrast medium Intravenous intraarterial administration iodinate contrast medium within previous 24 hour baseline CT scan Known hereditary ( e.g. , hemophilia ) acquire hemorrhagic diathesis , coagulation factor deficiency , anticoagulant therapy INR &gt; 1.2 Known suspect thrombocytopenia ( unless current platelet count document 50,000 / μl ) Unfractionated heparin use abnormal PTT Lowmolecular weight heparin use within previous 24 hour GPIIb/IIIa antagonist use previous two week Glasgow Coma Scale score &lt; 8 time propose enrollment Preadmission modify Rankin Scale score &gt; 2 Baseline ICH volume &lt; 0.5 cc ( Hematoma volume estimate local investigator baseline CT use ABC / 2 method . ) Baseline ICH volume &gt; 90 cc Planned surgical evacuation ICH within 24 hour symptom onset ( placement intraventricular catheter contraindication study enrollment . ) Evidence acute subacute ischemic stroke baseline qualify CT scan Clinical history thromboembolism ischemic vascular disease , include myocardial infarction , coronary artery bypass surgery , cardiac angina , transient ischemic attack , ischemic stroke , peripheral artery disease ( vascular claudication ) , cerebral bypass surgery , carotid endarterectomy , deep venous thrombosis , pulmonary embolism , coronary cerebrovascular angioplasty stenting . ( Clinically silent evidence old ischemia EKG ( Q wave ) CT scan ( silent old infarct ) consider reason exclusion . ) Baseline electrocardiogram show evidence acute cardiac ischemia ( ST elevation two contiguous lead , new LBBB , ST depression ) Clinical history suggestive acute cardiac ischemia ( e.g. , chest pain ) Abnormal baseline troponin Females childbearing potential know pregnant and/or lactate positive pregnancy test admission Advanced terminal illness condition investigator feel would pose significant hazard patient rFVIIa administer Recent ( within 30 day ) participation investigational drug device trial earlier participation investigational drug device trial duration effect expect persist time STOPIT enrollment Planned withdrawal care comfort care measure Patient know suspect able comply trial protocol ( e.g. , due alcoholism , drug dependency psychological disorder ) Informed consent obtain patient legally authorize representative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>intracerebral hemorrhage</keyword>
	<keyword>ICH</keyword>
	<keyword>compute tomography angiography</keyword>
	<keyword>CTA</keyword>
	<keyword>recombinant activate factor seven</keyword>
	<keyword>rFVIIa</keyword>
	<keyword>NovoSeven</keyword>
	<keyword>recombinant activate factor VII</keyword>
</DOC>